Eva Hellström Lindberg
I am double specialist in hematology and internal medicine since 1993, and professor of hematology at the Department of Medicine, Huddinge since 2009. I have worked within the translational research field for many years and been actively involved in strategic research questions. I have been president both for European Association of Hematology and for Swedish Society of Hematology.
My research program focuses on the hemopoietic stem cell malignancy myelodysplastic syndromes (MDS) and include genetic, epigenetic, and cellular studies. The aim is to understand mechanisms for disease progression, leukemic transformation, and erythroid failure. I also lead a clinical specialist program for patients with this disease, as well as the Nordic MDS research group, which drives a broad clinical trial and biomarker program. I am also chair for the newly started Center for Hematology and Regenerative Medicine, Huddinge, a translational research environment combining basic and clinical competences within hematology, regenerative medicine and immunology.
Selected recent publications
Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes. Rydén J, Edgren G, Karimi M, Walldin G, Tobiasson M, Wikman A, et al Leukemia 2019 02;33(2):522-527
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Shiozawa Y, Malcovati L, Gallì A, Sato-Otsubo A, Kataoka K, Sato Y, et al Nat Commun 2018 09;9(1):3649
Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells. Guzzi N, Cieśla M, Ngoc PCT, Lang S, Arora S, Dimitriou M, et al Cell 2018 05;173(5):1204-1216.e26
Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment. Scharenberg C, Jansson M, Saft L, Hellström-Lindberg E Br. J. Haematol. 2018 02;180(4):526-533
SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. Mortera-Blanco T, Dimitriou M, Woll PS, Karimi M, Elvarsdottir E, Conte S, et al Blood 2017 08;130(7):881-890
Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease. Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, De Paepe A, et al Oncotarget 2017 Apr;8(17):28812-28825
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, et al J. Intern. Med. 2017 03;281(3):284-299
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. Scharenberg C, Giai V, Pellagatti A, Saft L, Dimitriou M, Jansson M, et al Haematologica 2017 03;102(3):498-508
Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality. Dimitriou M, Woll PS, Mortera-Blanco T, Karimi M, Wedge DC, Doolittle H, et al Oncotarget 2016 Nov;7(45):72685-72698
I was previously involved in graduate training within ethics and communication skills, but is presently more focused on creating a good environment for post graduate student. I was chair for doctoral studies at the department for medicine for five years.
Academic honours, awards and prizes
- I have received both junior and senior research awards from the Swedish Cancer Society.
- In 2018 I received a Wallenberg Clinical Scholar grant; 3 million per year for 5 years.
- In 2016, I received José Carreras Award: This year's premier hematological award in Europe.